<code id='8D8900D308'></code><style id='8D8900D308'></style>
    • <acronym id='8D8900D308'></acronym>
      <center id='8D8900D308'><center id='8D8900D308'><tfoot id='8D8900D308'></tfoot></center><abbr id='8D8900D308'><dir id='8D8900D308'><tfoot id='8D8900D308'></tfoot><noframes id='8D8900D308'>

    • <optgroup id='8D8900D308'><strike id='8D8900D308'><sup id='8D8900D308'></sup></strike><code id='8D8900D308'></code></optgroup>
        1. <b id='8D8900D308'><label id='8D8900D308'><select id='8D8900D308'><dt id='8D8900D308'><span id='8D8900D308'></span></dt></select></label></b><u id='8D8900D308'></u>
          <i id='8D8900D308'><strike id='8D8900D308'><tt id='8D8900D308'><pre id='8D8900D308'></pre></tt></strike></i>

          focus

          focus

          author:Wikipedia    Page View:394
          Good CEOs 2022
          Hyacinth Empinado/STAT

          It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

          This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

          advertisement

          What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          What does generative AI mean for health care? We asked experts
          What does generative AI mean for health care? We asked experts

          MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

          read more
          Why Novartis is going to walk from its acquisition of MorphoSys
          Why Novartis is going to walk from its acquisition of MorphoSys

          MollyFerguson/STATNovartissaidMondaythatitintendstobuyMorphoSysforjustunder$3billion.Thedealwillnotc

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Surgery pushed Ben Carson to fame

          Drs.BenCarson,right,andDonlinLongwithabrainmodeloftheconjoinedtwinsthatwereseparatedinasurgeryperfor